By Rory Carroll and Andrew Chung SAN JOSE (Reuters) – Merck & Co told a federal jury on Tuesday it was seeking more than $2 billion in damages from rival Gilead Sciences Inc after the jury upheld the validity of two Merck patents in a high-profile dispute over Gilead's blockbuster cure for hepatitis C. After returning its verdict in favor of Merck on Tuesday, the jury in San Jose, California immediately began hearing evidence on how much Gilead owes Merck for infringing the patents. Bruce Genderson, an attorney for Merck, said the company is seeking a 10 percent royalty on Gilead's U.S. sales of nearly $21 billion for 2014 and 2015.
Here is the original:
Merck patents on Hepatitis C treatment found valid in Gilead dispute
